<DOC>
	<DOCNO>NCT00003822</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness SR-45023A treating patient advance solid tumor .</brief_summary>
	<brief_title>SR-45023A Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose SR-45023A patient locally advance metastatic solid tumor refractory standard therapy exists . II . Determine quantitative toxic effect SR-45023A patient . III . Assess pharmacokinetic profile SR-45023A patient . IV . Identify antitumor activity SR-45023A patient . OUTLINE : This dose escalation study . Patients receive oral SR-45023A twice daily 14 day , follow 7 day rest . On day 14 course 1 , patient receive one dose therapy due pharmacokinetic sampling . Treatment continue every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos SR-45023A maximum tolerate dose ( MTD ) reach . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow death . PROJECTED ACCRUAL : Up 30 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advanced metastatic solid tumor refractory standard therapy standard therapy exist ( surgery , radiotherapy , and/or chemotherapy ) Measurable evaluable disease medical photograph , plain xray , CT , MRI , palpation , serum tumor marker least 2 time upper limit normal No asymptomatic brain metastases No leukemia , lymphoma , multiple myeloma PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 01 Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL No coagulation disorder Hepatic : Bilirubin normal AST ALT great 3 time upper limit normal ( ULN ) ( great 5 time ULN liver involvement ) Renal : Creatinine le 1.5 mg/dL Creatinine clearance least 45 mL/min Cardiovascular : No cardiac conduction abnormalities Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection No concurrent serious systemic disorder No concurrent recent ( within past 6 month ) small bowel obstruction , symptom small bowel obstruction , gastrointestinal disease PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy No concurrent filgrastim ( GCSF ) Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy recover No prior SR45023A No concurrent chemotherapy Endocrine therapy : No concurrent hormonal cancer therapy ( except contraception , hormone replacement therapy , corticosteroid ) Radiotherapy : See Disease Characteristics Prior radiotherapy allow less 25 % bone marrow recover No prior radiotherapy whole pelvis No concurrent radiotherapy Surgery : See Disease Characteristics Other : At least 4 week since prior investigational agent No concurrent investigational agent No concurrent anticoagulation therapy ( e.g. , Coumadin heparin ) No concurrent digoxin , beta blocker , calcium channel blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2001</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>